Parker-Hannifin
PH · NYSE
About PH
- Employees
- 57,950
- Headquarters
- CLEVELAND, Ohio
- Listed
- Dec 9, 1964
- Sector
- Industrials
- Industry
- Machinery
- Website
- parker.com
PH key statistics
- Market cap
- 119.13B
- Price-earnings ratio
- 33.93
- Dividend yield
- 0.78%
- Average volume
- 503.82K
- Volume
- 661.88K
- Open price
- $959.14
- High today
- $960.29
- Low today
- $931.51
- 52 Week high
- $1,099.94
- 52 Week low
- $734.72
Parker-Hannifin (PH) at a glance
As of Oct 20, 2026, Parker-Hannifin (PH) shares are priced at $944.61, giving the company a market cap of 119.13B, a price-to-earnings ratio of 33.93 and a dividend yield of 0.78%.
Today the stock has traded between $931.51 and $960.29. The current price is 1.4% above the day's low and 1.6% below its high.
Volume so far is 661.88K shares, above the average of 503.82K shares a day.
Over the past year Parker-Hannifin has ranged from $734.72 to $1,099.94, and now sits 57% of the way up that range.
Parker-Hannifin met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $9.27 per share against an estimate of $8.51.
The average analyst price target is $1,179.89, 24.9% above the current price, from 22 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
- Buy81.8%
- Hold18.2%
- Sell0.0%
- Low
- $700.54
- Now
- $944.61
- High
- $1,425.90
PH earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 7 of the last 8 quarters, by 3.7% on average.
- Q3 FY24: reported $6.51 per share against an estimate of $6.33
- Q4 FY24: reported $6.77 per share against an estimate of $6.41
- Q1 FY25: reported $6.20 per share against an estimate of $6.33
- Q2 FY25: reported $6.53 per share against an estimate of $6.42
- Q3 FY25: reported $6.94 per share against an estimate of $6.92
- Q4 FY25: reported $7.69 per share against an estimate of $7.32
- Q1 FY26: reported $8.17 per share against an estimate of $8.07
- Q2 FY26: reported $9.27 per share against an estimate of $8.51
PH news
- Chris Katje
- Piero Cingari
Philadelphia Factory Optimism Hits 43-Year Highs: Investors 'MADE' This Trade
- Caroline Ryan
Deal Dispatch: Safe Harbor Marinas Buys MarineMax, Thoma Bravo Acquires Accelerant, 777 Partners Bankruptcy
- Akanksha Bakshi
Parker Hannifin Stock Hits 52-Week High - Here's Why
- Press releaseGlobe Newswire
Parker Reports Record Fiscal 2026 Fourth Quarter and Full Year Results
10 Industrials Stocks With Whale Alerts In Today’s Session
- Chris Katje
Congressman Looking For Dividends? Taylor Ditches 2 Magnificent Seven Stocks For Blue Chips
- Caroline Ryan
Deal Dispatch: IMAX Mulls Potential Sale, Shein Buys Everlane, West Marine Bankruptcy
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.